A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Crenigacestat (Primary) ; Dexamethasone (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 07 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 16 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.